Pharmacokinetic considerations for new targeted therapies

Clin Pharmacol Ther. 2009 Feb;85(2):208-11. doi: 10.1038/clpt.2008.242. Epub 2008 Dec 17.


Targeted therapies are increasingly being incorporated into standard treatment regimens for cancer. Tyrosine kinase inhibitors represent one class of targeted agents, with eight drugs receiving approval for the treatment of cancer in recent years. Although they hold the promise of being more effective and less toxic to normal cells than conventional cytotoxic chemotherapy, tyrosine kinase inhibitors are associated with different adverse effects, sometimes severe, as well as wide pharmacokinetic variability. Thus, a “therapeutic window” may exist for these agents.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Drug Delivery Systems / methods*
  • Drug Delivery Systems / trends
  • Humans
  • Neoplasms / drug therapy
  • Neoplasms / enzymology
  • Pharmacokinetics*
  • Protein Kinase Inhibitors / administration & dosage
  • Protein Kinase Inhibitors / pharmacokinetics


  • Protein Kinase Inhibitors